ChanTest is a provider of services to facilitate drug discovery, development and safety testing. ChanTest has developed an extensive library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. Services range from early functional screens for profiling drug candidates or ranking within profiles during the drug-discovery process – to a complete set of in vitro GLP service products for cardiac risk assessment. ChanTest works in partnership with customers to speed the drug-development process, save time and reduce costs, and ultimately to help make better, safer drugs. ChanTest will spin out technology into a second company, ChanXpress Inc., to develop a line of anti-arrhythmic drugs, which are intended to reduce irregular heart rates and seizures that precede heart attacks.